Why the study?
Does Vitamin K Antagonist (VKA) therapy reduce thromboembolism or mortality in patients undergoing bioprosthetic valve implantation?
Does Vitamin K Antagonist (VKA) therapy reduce thromboembolism or mortality in patients undergoing bioprosthetic valve implantation?
In patients undergoing bioprosthetic valve implantation, VKA therapy does not reduce thromboembolism or mortality compared to antiplatelet or no therapy, but significantly increases the risk of major bleeding.
Avoid adding VKA after bioprosthetic valve implantation; challenges prior recommendations by showing increased bleeding without thromboembolic or mortality benefit.
In a meta-analysis of randomised and observational studies of VKA versus AP/no treatment in patients undergoing bioprosthetic valve implantation, there was no benefit of adding a VKA regarding thromboembolism or mortality. However, use of a VKA was associated with increased risk of major bleeding.
No takes yet. Share an insight, caveat, or question.
Masri et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: